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ABSTRACT
The functional role of nuclear factor of activated T-cells (NFAT), a key regulator 
of the immune response, in bladder cancer progression remains uncertain. In 
this study, we assessed biological significance of NFAT in human bladder cancer. 
Immunohistochemistry detected nuclear/cytoplasmic NFATc1 signals in 14 
(21.5%)/34 (52.3%), respectively, of 65 muscle-invasive bladder carcinomas and 
showed that patients with nuclear NFATc1-positive tumor had a significantly higher risk 
of disease progression (P = 0.006). In bladder cancer cell lines, cyclosporine A (CsA) 
and tacrolimus (FK506), immunosuppressant drugs/non-selective NFAT inhibitors, 
attenuated NFATc1 expression and its nuclear translocation, NFAT transcriptional 
activity, and the expression of cyclooxygenase-2 and c-myc, downstream targets of 
NFATc1. NFAT inhibition via NFATc1-small interfering RNA (siRNA) or treatment with 
these NFAT inhibitors resulted in decreases in cell viability/colony formation, cell 
migration/invasion, and the expression/activity of MMP-2 and MMP-9, as well as an 
increase in apoptosis, in the parental/control lines. No significant additional inhibition 
in the viability and invasion of NFATc1-siRNA cells was seen. In xenograft-bearing 
mice, CsA and FK506 significantly retarded tumor growth. These results suggest 
that NFATc1 plays an important role in bladder cancer outgrowth. Thus, NFATc1 
inactivation, especially using CsA and FK506, has the potential of being a therapeutic 
approach for bladder cancer.
INTRODUCTION
Nuclear factor of activated T-cells (NFAT), initially 
identified as a regulator of T-cell activation [1], has 
subsequently been characterized mainly in immune cells 
[2]. NFAT family members, including NFATc1 (also 
known as NFAT2), NFATc2 (NFAT1), NFATc3 (NFAT4), 
and NFATc4 (NFAT3), are located in the cytoplasm of 
immune cells (e.g. lymphocyte) in a hyperphosphorylated 
state and translocate into the nucleus upon cell stimulation 
by their dephosphorylation in response to Ca2+-calcineurin 
signals [2, 3]. The nuclear NFATs then form heterodimers 
with other transcription factors and induce downstream 
gene transcription. Interest in NFAT signaling was further 
enhanced by the observation indicating that cyclosporine 
A (CsA) and tacrolimus (FK506), immunosuppressants 
widely used in transplant medicine, specifically inactivated 
the NFAT pathway [4].
There is an increasing amount of evidence suggesting 
that NFAT signaling contributes to the development and 
progression of not only hematological malignancies but also 
solid tumors. Expression levels of NFAT isoforms, especially 
NFATc1, have been assessed in several types of cancer tissue 
specimens. Indeed, NFATc1 overexpression was detected in 
pancreatic [5], lung [6], and liver [7] carcinomas. Further 
functional analyses have revealed NFAT isoform-specific 
involvement in cancer progression, as seen in the regulation 
of hematopoietic system. In particular, NFATc1 was shown 
to promote tumor growth via, for instance, induction of 
c-myc in pancreatic cancer [5], cyclooxygenase (COX)-
2 in melanoma [8], and autotaxin/lysophosphatidic acid 
axis in breast cancer [9]. In a sarcoma model, NFATc1 was 
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also found to be oncogenic, whereas NFATc2 functioned 
as a tumor suppressor [10]. Moreover, NFATc1 has been 
implicated, as a key regulator, in lymphangiogenesis [11]. 
On the other hand, little is known about the specific roles 
of NFATc3, NFATc4, and NFAT5 in tumorigenesis and 
tumor progression, although inhibition of breast cancer cell 
motility by NFATc4 has been reported [12].
The functional role of NFAT signaling in bladder 
cancer progression remains largely unknown. In 
the current study, we investigated whether NFATc1 
inactivation inhibited the growth of bladder cancer cells.
RESULTS
Expression of NFATc1 in human bladder cancer
We first examined the expression of NFATc1 in 
human urothelial carcinoma cell lines, UMUC3, TCCSUP, 
647V, and 5637, and an immortalized human normal 
urothelial cell line, SVHUC, by western blotting (Fig. 1A) 
and reverse transcription (RT)-polymerase chain reaction 
(PCR) (Fig. 1B). All four bladder cancer lines were found 
to express NFATc1 at both protein and mRNA levels, and 
its expression in the benign urothelial line was weaker.
We next stained immunohistochemically for NFATc1 
in the bladder tissue microarrays (TMAs) consisting of 65 
cases of invasive bladder cancer. Positive signals were 
detected in both the nucleus and cytoplasm of tumor 
cells (Fig. 1C). Nuclear NFATc1 was positive in 14 cases 
[21.5%; 9 (13.8%) 1+, 4 (6.2%) 2+, and 1 (1.5%) 3+] and 
cytoplasmic NFATc1 was positive in 34 cases [52.3%; 19 
(29.2%) 1+, 8 (12.3%) 2+, and 7 (10.8%) 3+] (Table 1). 
Spearman’s correlation analysis revealed a positive 
correlation between nuclear versus cytoplasmic expression 
of NFATc1 (R2 = 0.2117; P < 0.001). Meanwhile, there were 
no statistically significant correlations between nuclear or 
cytoplasmic positivity of NFATc1 and patient age, gender, 
pT stage, or status of lymph node involvement. Kaplan-Meier 
analysis coupled with log-rank test further showed a strong 
association between nuclear expression of NFATc1 (P = 
0.006; Fig. 1D), but not its cytoplasmic positivity (P = 0.164; 
figure not shown), and disease progression after cystectomy.
Down-regulation of NFAT by CsA and FK506 in 
bladder cancer cells
We determined the effects of CsA and FK506, which 
were known to inhibit NFAT signals in immune cells [4], 
on NFATc1 expression by western blotting, RT-PCR, 
and immunofluorescence in bladder cancer cells. NFAT-
mediated transcriptional activity was also determined in 
the cell extracts with transfection of a NFAT luciferase 
reporter plasmid. As expected, transfection of a NFATc1-
small interfering RNA (siRNA) silenced endogenous 
NFATc1 protein (Fig. 2A) and mRNA (Fig. 2B) in UMUC3 
cells. Similarly, CsA and FK506 both at 1 μM reduced 
NFATc1 gene expression in all bladder cancer cell lines 
tested (Fig. 2B). Subcellular localization of NFATc1 was 
then examined in UMUC3 by western blotting: treatment 
with CsA or FK506 resulted in decreases in nuclear 
NFATc1 expression as well as an increase in cytoplasmic 
NFATc1 expression (marginal change by CsA) (Fig. 2C). 
Inhibition of nuclear translocation of NFATc1 was further 
confirmed by immunofluorescence (Fig. 2D). Additionally, 
NFATc1-siRNA as well as CsA and FK506 decreased 
NFAT luciferase activity, compared with control-siRNA 
transfection or mock treatment (Fig. 2E). Significant but 
only 20% reduction in NFAT activity by the NFATc1-
siRNA might be due to silencing of only one of NFAT 
isoforms. To confirm the down-regulation of NFAT activity 
by CsA and FK506, we measured expression levels of 
COX-2 and c-myc, downstream targets of NFATc1 signals 
Figure 1: Expression of NFATc1 in bladder cancer. (A) Western blotting of NFATc1 in urothelial cell lines. Total protein extracted 
from each cell line was immunoblotted for NFATc1 (105 kDa). GAPDH (37 kDa) served as an internal control. Densitometry values 
for specific bands standardized by GAPDH that are relative to the value in SVHUC cells are included below the lanes. (B) Quantitative 
RT-PCR of NFATc1 in urothelial cell lines. Total RNA isolated from each cell line was subjected to real-time RT-PCR. Expression of NFATc1 
gene was normalized to that of GAPDH. Transcription amount is presented relative to that in SVHUC. Each value represents the mean 
(+SD)  from at least three independent experiments. (C) Immunohistochemistry of NFATc1 in bladder cancer specimens. (D) Progression-
free survival rates in patients with invasive bladder cancer. Kaplan-Meier analysis was performed according to the expression of NFATc1, 
and comparison was made by log-rank test.
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[5, 8]. Significant decreases in COX-2 protein (Fig. 2F)/
mRNA (Fig. 2G) and c-myc mRNA (Fig. 2H) by NFATc1-
siRNA and CsA/FK506 were also seen. These results 
indicate that CsA and FK506 down-regulate the expression 
and activity of NFATc1 in bladder cancer cells.
Anti-proliferative effects of CsA and FK506 in 
bladder cancer cells
To determine whether NFATc1 down-regulation 
exerts an influence on the proliferation of bladder cancer 
cells, we assessed cell viability [by methylthiazolyldiphenyl-
tetrazolium (MTT) assay] and colony formation (by 
clonogenic assay) in bladder cancer lines treated with CsA 
or FK506. In the parental cell lines, CsA and FK506 strongly 
suppressed their growth (Fig. 3A). Similar inhibition by CsA 
and FK506 was observed in UMUC3-control-siRNA cells 
(Fig. 3B). However, there were no significant additional 
decreases in the growth of UMUC3-NFATc1-siRNA cells, 
while an inhibitory effect of NFATc1-siRNA, compared with 
UMUC3-control-siRNA, was seen (Fig. 3B), suggesting the 
suppression by CsA or FK506 predominantly via NFATc1. 
Both CsA and FK506 were also found to decrease the number 
and area of colonies in UMUC3 and TCCSUP cells (Fig. 3C).
To investigate how CsA and FK506 inhibit cell 
proliferation, we performed terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling (TUNEL) 
assay (Fig. 3D) and flow cytometry (Fig. 3E). CsA or 
FK506 treatment for 24 hours significantly increased 
apoptotic indices. By contrast, these only marginally 
changed the G0/G1 population.
Suppressive effects of CsA and FK506 on 
bladder cancer cell migration and invasion
Cell migration and invasion are critical steps 
during tumor progression and metastasis. We therefore 
performed a scratch wound healing assay and a transwell 
invasion assay to assess the effects of NFATc1 inhibition 
on cell migration and invasion, respectively, in bladder 
cancer lines. In the wound healing assay, CsA and FK506 
significantly delayed wound closure (Fig. 4A). Similarly, 
in the transwell assay, CsA and FK506 treatment 
demonstrated marked decreases in cell invasion ability 
(Fig. 4B). NFATc1 knock-down resulted in a significant 
decrease in the invasive properties, compared with the 
control line, while no significant effects of CsA and 
FK506 on cell invasion were seen in the NFATc1-siRNA 
line (Fig. 4C). Using a quantitative RT-PCR method, 
we then analyzed the effects of CsA and FK506 on the 
expression of matrix metalloproteinases (MMPs) that 
are known to play a critical role in cancer cell migration/
invasion, angiogenesis, and resultant tumor progression 
and metastasis. CsA and FK506 decreased the levels 
of MMP-2 and MMP-9 expression, compared with the 
vehicle control, in two cell lines, except CsA for MMP-9 
in TCCSUP (Fig. 4D). We also determined the enzymatic 
activity of MMP-2 and MMP-9 by gelatin zymography 
Table 1: Expression of NFATc1 in bladder cancer tissue microarrays
n
Expression levels
P valueNegative  Positive
0 1+ 2+ 3+ 0 vs. 1+/2+/3+
Nucleus
Total 65 51 (78.5%) 9 (13.8%) 4 (6.2%) 1 (1.5%)
pT2 23 18 (78.3%) 4 (17.4%) 0 (0.0%) 1 (4.3%)
0.920pT3 31 25 (80.6%) 4 (12.9%) 2 (6.5%) 0 (0.0%)
pT4 11 8 (72.7%) 1 (9.1%) 2 (18.2%) 0 (0.0%)
pN0 39 30 (76.9%) 7 (17.9%) 1 (2.6%) 1 (2.6%)
1.000
pN+ 21 16 (76.2%) 2 (9.5%) 3 (14.3%) 0 (0.0%)
Cytoplasm
Total 65 31 (47.7%) 19 (29.2%) 8 (12.3%) 7 (10.8%)
pT2 23 12 (52.2%) 7 (30.4%) 2 (8.7%) 2 (8.7%)
0.331pT3 31 16 (51.6%) 8 (25.8%) 3 (9.7%) 4 (12.9%)
pT4 11 3 (27.3%) 4 (36.4%) 3 (27.3%) 1 (9.1%)
pN0 39 22 (56.4%) 11 (28.2%) 4 (10.3%) 2 (5.1%)
0.109
pN+ 21 7 (33.3%) 7 (33.3%) 2 (9.5%) 5 (23.8%)
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Figure 2: Inactivation of NFATc1 in bladder cancer. (A) Western blotting of NFATc1 in UMUC3 cells transfected with control-siRNA 
or NFATc1-siRNA. Cell extracts were immunoblotted for NFATc1 (105 kDa). GAPDH (37 kDa) served as an internal control. (B) Quantitative 
RT-PCR of NFATc1 in bladder cancer cells. UMUC3 cells expressing control-siRNA or NFATc1-siRNA and UMUC3/TCCSUP/647V cells treated 
with ethanol (mock), CsA (1 μM), or FK506 (1 μM) for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR. Expression 
of NFATc1 gene was normalized to that of GAPDH. Transcription amount is presented relative to that of control-siRNA expression or mock 
treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. *P < 0.05 (vs. mock treatment). 
**P < 0.01 (vs. mock treatment). ***P < 0.001 (vs. control-siRNA). (C) Western blotting of NFATc1 in UMUC3 cells treated by ethanol 
(mock), CsA (1 μM), or FK506 (1 μM) for 24 hours. Separate nuclear and cytoplasmic protein fractions were immunoblotted for NFATc1. 
(D) Immunofluorescent staining of NFATc1 in UMUC3 cells treated with ethanol (mock), CsA (1 μM), or FK506 (1 μM), along with ionomycin 
(1 μM) to induce nuclear translocation of NFATc1, for 30 minutes before formalin fixation. We merged the images between NFATc1 and DAPI 
that was used to visualize nuclei. Cytoplasmic signals of NFATc1 are seen in the CsA- and FK506-treated cells, but not in the mock-treated cell. 
(E) NFAT luciferase reporter activity in bladder cancer cells. UMUC3, with or without co-expression of control-siRNA or NFATc1-siRNA, or 
TCCSUP cells were transfected with pGL4.30-NFAT-response element and pRL-TK and subsequently cultured with ethanol (mock), CsA (1 μM), 
or FK506 (1 μM) for 24 hours. Luciferase activity is presented relative to that of control-siRNA expression or mock treatment in each cell line. Each 
value represents the mean (+SD) from at least three independent experiments. *P < 0.05 (vs. mock treatment in each cell line). ***P < 0.001 (vs. 
control-siRNA). (F) Western blotting of COX-2 in UMUC3 cells either transfected with control-siRNA or NFATc1-siRNA or treated with ethanol 
(mock), CsA (1 μM), or FK506 (1 μM) for 24 hours. Cell extracts were immunoblotted for COX-2 (69 kDa) and GAPDH. Quantitative RT-PCR of 
COX-2 (G) and c-myc (H) in bladder cancer cells. UMUC3 cells expressing control-siRNA or NFATc1-siRNA and UMUC3/TCCSUP cells treated 
with ethanol (mock), CsA (1 μM), or FK506 (1 μM) for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR. Expression 
of  COX-2 or c-myc gene was normalized to that of GAPDH. Transcription amount is presented relative to that of control-siRNA expression or 
mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. *P < 0.05 (vs. mock treatment 
in each cell line). **P < 0.01 (vs. control-siRNA or mock treatment in each cell line). ***P < 0.001 (vs. mock treatment in each cell line).
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Figure 3: Effects of NFAT inactivation on bladder cancer cell proliferation. MTT assay in UMUC3/TCCSUP/647V/5637 
(A) or UMUC3 transfected with control-siRNA or NFATc1-siRNA (B). The cells were cultured in the presence of ethanol (mock), CsA (1 μM), 
or FK506 (1 μM) for 4 days and their viability was assessed with MTT. Growth suppression is presented relative to that of mock treatment 
in each cell line (A) or mock treatment/control-siRNA expression (B). Each value represents the mean (+SD) from at least three independent 
experiments. **P < 0.01 (vs. mock treatment). ***P < 0.001 (vs. mock treatment in each cell line). ###P < 0.001 (vs. mock treatment in 
control-siRNA cells). (C) Clonogenic assay in UMUC3 and TCCSUP cells cultured in the presence of ethanol (mock), CsA (1 μM), or FK506 
(1 μM) for 2 weeks. The number of colonies and their areas quantitated, using the ImageJ software, are presented relative to those of mock 
treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. *P < 0.05 (vs. mock treatment). 
**P < 0.01 (vs. mock treatment). ***P < 0.001 (vs. mock treatment in each cell line). (D) TUNEL assay in UMUC3 and TCCSUP cells cultured 
in the presence of ethanol (mock), CsA (1 μM), or FK506 (1 μM) for 24 hours. Apoptosis (percentage of TUNEL-positive cells) is presented 
relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. *P < 0.05 
(vs. mock treatment). **P < 0.01 (vs. mock treatment). (E) Flow cytometry in UMUC3 and TCCSUP cells cultured in the presence of ethanol 
(mock), CsA (1 μM), or FK506 (1 μM) for 24 hours. P-values (vs. mock treatment in each cell line).
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Figure 4: Effects of NFAT inactivation on cell migration and invasion. (A) Wound healing assay in UMUC3/TCCSUP/647V/5637 
cells. The cells grown to confluence were gently scratched and the wound area was measured after 24-hour culture with ethanol (mock), CsA 
(1 μM), or FK506 (1 μM). The migration determined by the rate of cells filling the wound area is presented relative to that of mock treatment in 
each cell line. Each value represents the mean (+SD) from at least three independent experiments. *P < 0.05 (vs. mock treatment in each cell line). 
**P < 0.01 (vs. mock treatment in each cell line). Transwell invasion assay in UMUC3/TCCSUP (B) or UMUC3 transfected with control-siRNA 
or NFATc1-siRNA (C). The cells were cultured in the Matrigel-coated transwell chamber for 24 hours in the presence of ethanol (mock), CsA 
(1 μM), or FK506 (1 μM). The number of invaded cells present in the lower chamber was counted under a light microscope (10x objective in five 
random fields). Cell invasion is presented relative to that of mock treatment in each cell line (B) or mock treatment/control-siRNA expression 
(C). Each value represents the mean (+SD) from three independent experiments. **P < 0.01 (vs. mock treatment in each cell line). ***P < 0.01 
(vs. mock treatment). #P < 0.05 (vs. mock treatment in control-siRNA cells). ##P < 0.01 (vs. mock treatment in control-siRNA cells). ###P < 0.001 
(vs. mock treatment in control-siRNA cells). (D) Quantitative RT-PCR of MMP-2 and MMP-9 in bladder cancer cells. UMUC3 and TCCSUP 
cells treated with ethanol (mock), CsA (1 μM), or FK506 (1 μM) for 24 hours were subjected to RNA extraction and subsequent real-time 
RT-PCR. Expression of each specific gene was normalized to that of GAPDH. Transcription amount is presented relative to that of mock treatment 
in each cell line. Each value represents the mean (+SD) from at least three independent experiments. *P < 0.05 (vs. mock treatment in each 
cell line). ***P < 0.001 (vs. mock treatment). (E) MMP-2/MMP-9 activity in bladder cancer cells. UMUC3 and TCCSUP cells cultured in serum-
free medium in the presence of ethanol (mock), CsA (1 μM), or FK506 (1 μM) were subjected to gelatin zymography. The activity of MMP-2 
(72 kDa) or MMP-9 (92 kDa) was indicated by clear zones of gelatin lysis against a blue background of stained substrate.
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and showed considerable decreases in those of MMP-9 in 
UMUC3 and MMP-2 in TCCSUP in the presence of CsA 
and FK506 (Fig. 4E).
Anti-tumor activity of CsA and FK506 in a 
mouse xenograft model for bladder cancer
Finally, we used a mouse xenograft model to 
investigate whether CsA and FK506 inhibit bladder 
tumor growth in vivo. UMUC3 cells were implanted 
subcutaneously into the flank of SCID mice, and after 2–3 
weeks, when the estimated tumor volume reached 100 
mm3, we commenced daily injections of CsA or FK506 
(Fig. 5A). As shown in Fig. 5B, the inoculated tumors in 
mice treated with CsA or FK506 were significantly smaller 
than those in the control mice at 12–16 days of treatment. 
CsA and FK506 also prevented the growth of tumors 
exceeding 2,000 mm3 or 10% of the animal’s body weight 
(Fig. 5C). Immunohistochemical staining in the harvested 
specimens revealed decreases in NFATc1 expression 
(Fig. 5D) and cell proliferation as the percentage of 
Ki-67-positive cells (Fig. 5E) in CsA/FK506-treated 
tumors. These in vivo data further suggest that CsA and 
FK506 strongly inhibit the progression of bladder cancer.
DISCUSSION
In contrast to a wide range of biological functions of 
NFATs in the immune system that have been recognized, 
an increasing, yet limited, amount of evidence suggests 
their involvement in the progression of solid tumors. In 
particular, their roles in bladder cancer progression remain 
largely unknown. In the present study, we demonstrate that 
NFATc1 inactivation via NFATc1-siRNA as well as CsA 
and FK506 results in bladder tumor regression.
Intracellular calcium-mediated calcineurin signaling 
and subsequent activation of the NFAT pathway, without 
specifying the involvement of its isoforms, have been 
implicated in cell proliferation of prostatic [13, 14] and 
endometrial [15] carcinomas. It has also been shown that 
NFATc1 activation promotes liver cancer cell proliferation 
[7] and breast cancer cell migration [9]. Potential 
downstream targets of NFATc1 for its regulation of 
cancer cell growth include c-myc, COX-2, and autotaxin 
[5, 7–9], all of which are known to involve stimulation 
of cancer cell proliferation and invasion, chemotaxis, 
and/or metastasis. Using bladder cancer lines, we here 
demonstrated that they overexpressed NFATc1 and that 
silencing of NFATc1 resulted in significant decreases, 
similar to those by CsA or FK506 treatment, in cell 
viability and invasion. These results further suggest that, 
among NFAT isoforms, NFATc1 plays a dominant role 
in bladder cancer progression. However, in other types 
of malignancies, other isoforms (e.g. NFATc2) were also 
shown to contribute to the promotion of tumor progression 
[16, 17], while inhibitory functions of NFATc2 [10] and 
NFATc4 [12] were noted. Therefore, each isoform is 
likely to specifically regulate downstream targets as well 
as tumor progression or regression in different types of 
cancers.
Correspondingly, overexpression of NFAT isoforms 
in several types of malignancies, other than bladder 
cancer, has been reported. Of these, the expression levels 
of NFATc1 were often elevated [5–7]. In these studies, 
localization of NFATc1 detected by immunohistochemical 
staining (i.e. nuclear vs. cytoplasmic signals) appeared 
to be cancer type-dependent. For instance, both nuclear 
and cytoplasmic signals were detected in pancreatic 
[5] and lung [6] carcinomas, whereas predominant 
nuclear/cytoplasmic expression was seen in hepatocellular 
carcinoma [7]/subcutaneous T-cell lymphoma [18], 
respectively. Our immunohistochemistry for NFATc1 in 
muscle-invasive bladder cancers stained both the nuclei 
and cytoplasms. Although there were no significant 
correlations between the status of NFATc1 expression and 
clinicopathologic features available for our patient cohort, 
those with nuclear NFATc1-positive tumor were found to 
have a significantly higher risk of disease progression. 
Our recent immunohistochemical study in separate sets of 
bladder TMAs consisting of non-muscle-invasive tumors 
[19] also detected both nuclear and cytoplasmic NFATc1 
signals and further revealed significant increases in the 
level of its nuclear expression in urothelial neoplasm, 
compared with non-neoplastic urothelium, and in low-
grade or high-grade urothelial carcinoma, compared 
with papillary urothelial neoplasm of low malignant 
potential, a very low grade tumor that is neither benign 
nor intrinsically malignant [20]. Our staining results thus 
support other data suggesting that NFATc1 promotes 
bladder cancer progression.
The immunosuppressive drugs CsA and FK506 have 
been shown to inhibit the phosphatase activity of calcineurin 
in T-cells and thereby prevent nuclear translocation of 
NFAT/inactivate the NFAT pathway [4, 21]. We confirmed 
this in bladder cancer cells by demonstrating that CsA and 
FK506 reduced the overall and nuclear levels of NFATc1 
expression, suppressed the transcriptional activity of 
NFAT, and down-regulated the expression of COX-2 and 
c-myc. In addition, CsA and FK506 treatment inhibited cell 
viability, migration, and invasion of bladder cancer in vitro, 
and tumor growth in vivo. They also induced apoptosis, 
but not cell cycle arrest. Interestingly, these effects of CsA 
and FK506 were not seen in NFATc1 knock-down cell 
lines, suggesting that these non-selective NFAT inhibitors 
suppress bladder cancer growth predominantly through the 
NFATc1 pathway. Nonetheless, anti-proliferative effects 
of CsA via non-NFAT pathway have also been reported in 
colon cancer models [22].
As aforementioned, CsA and FK506 have often 
been prescribed in organ transplant recipients to 
prevent rejection as well as in a subset of patients with 
disorders related to autoimmunity. Treatment with these 
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immunosuppressants is associated with potentially serious 
side effects that are often closely related to their blood 
concentrations [23]. As a result, the doses of CsA and 
FK506 are often strictly adjusted to maintain their levels 
of not more than 1200 ng/mL (1.0 μM) and 20 ng/mL 
(25 nM), respectively. Thus, FK506 clinically shows 
similar immunosuppressive effects with up to 50-fold 
lower doses than CsA [24]. In our cell line studies, the 
same concentration (1 μM) of CsA and FK506 achieved 
similar inhibition, whereas, in our xenograft model, 
30 mg/Kg/day CsA and 3 mg/Kg/day FK506 showed 
similar effects. Therefore, CsA may be more potent 
in suppressing bladder cancer growth than FK506 
at their pharmacological concentrations. Indeed, a 
pharmacological dose (25 nM) of FK506 did not 
significantly inhibit cell viability of bladder cancer lines 
(data not shown). In prostate cancer lines, CsA showed 
more significant inhibitory effects on cell proliferation, 
compared with FK506 at the same concentrations up to 
10 μM [25]. Moreover, CsA was shown to inhibit the 
Figure 5: Effects of CsA and FK506 on tumor growth in a mouse xenograft model for bladder cancer. (A) CsA (30 
mg/kg/day), FK506 (3 mg/kg/day), or vehicle control was injected intraperitonealy in UMUC3-bearing NOD-SICD mice. (B) Tumor 
size was monitored every other days. *P < 0.05 (mock vs. FK506)/0.01 (mock vs. CsA). **P < 0.01 (mock vs. CsA or FK506). 
(C) Kaplan-Meier curves and log-rank test according to the endpoint set as tumor volume exceeding 2000 mm3 or 10% of animal’s body 
weight. (D) Immunohistochemical staining of NFATc1 in harvested xenograft tumors. Occasional NFATc1 signals (arrowheads) are seen 
in tumors from control mice, but not in those from CsA/FK506-treated mice. Tumor necrosis is noted in CsA/FK506-treated tumors. 
(E) Immunohistochemical staining of Ki-67 in harvested xenograft tumors. Mean values (± SD) of the percentage of Ki-67-positive tumor 
cells are shown. #Mock vs. CsA, P = 0.051. ***Mock vs. FK506, P < 0.001.
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growth of both androgen-sensitive and androgen receptor 
(AR)-negative prostate cancer lines, while FK506 inhibited 
only AR-dependent growth but failed to do in AR-
negative cells [25]. Although some bladder cancer lines 
are known to possess a functional AR [26–28], FK506 
(and CsA) similarly inhibited the growth of AR-positive 
(i.e. UMUC3, TCCSUP) versus AR-negative (i.e. 647V, 
5637) bladder cancer cells. Additionally, to prevent severe 
adverse drug reactions potentially seen with CsA or FK506 
treatment, a peptide that interferes with the calcineurin-
NFAT interaction [29, 30] and small molecule inhibitors 
of NFATs [31–33] have been developed and assessed 
mainly in animal models. The efficacy of these inhibitors 
in bladder cancer growth may also need to be tested.
In conclusion, NFATc1 likely plays an important 
role in bladder cancer progression. Our findings may also 
offer a potential therapeutic strategy for bladder cancer 
via targeting the calcineurin-NFAT pathways, especially 
NFATc1 signals. CsA (and FK506) may thus be able to 
be applied to the treatment of advanced bladder cancer. 
Further assessment of the functions of NFATc1 as well 
as other isoforms is required to determine biological 
significance of NFAT signaling in bladder cancer.
MATERIALS AND METHODS
Cell culture and chemicals
A human normal urothelial cell line (SVHUC) 
and human urothelial carcinoma cell lines (UMUC3, 
TCCSUP, and 5637) were originally obtained from the 
American Type Culture Collection. 647V cell line was 
used in our previous study [26]. All these lines were 
recently authenticated, using GenePrint 10 System 
(Promega), by the institutional core facility. SVHUC cells 
were maintained in F-12K (Mediatech) and other cell 
lines were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM; Mediatech), all supplemented with 
10% fetal bovine serum (FBS), penicillin (100 units/mL), 
and streptomycin (100 units/mL) at 37°C in a humidified 
atmosphere of 5% CO
2
. Cells were cultured in phenol red-
free medium supplemented with 5% charcoal-stripped 
FBS (CS-FBS) at least 24 hours before experimental 
treatment. A siRNA targeting NFATc1 (sc-29412; Santa 
Cruz Biotechnology) or a non-silencing control siRNA 
(sc-37007; Santa Cruz Biotechnology) was transfected at 
a final concentration of 20-80 nM into the bladder cancer 
lines, using GeneJuice (Novagen). We obtained CsA and 
FK506 from Abcam.
Cell proliferation
We used MTT assay to assess cell viability, as 
described previously [34]. Briefly, cells (1–3 x 103) 
seeded in 96-well tissue culture plates were incubated 
with DMEM supplemented with CS-FBS in the 
presence or absence of CsA or FK506. The media were 
refreshed every 48 hours. After 96 hours of treatment, 
10 μL MTT stock solution (5 mg/mL; Sigma) was added 
to each well with 100 μL of medium for 4 hours at 
37°C. The medium was replaced with 100 μL dimethyl 
sulfoxide, followed by incubation for 5 minutes at room 
temperature. The absorbance was then measured at a 
wavelength of 570 nm with background subtraction at 
655 nm using luminometer (FLUOstar Omega, BMG 
Labtech).
Reporter gene assay
Cells at a density of 50-70% confluence in 24-
well plates were co-transfected with 250 ng of pGL4.30 
NFAT reporter plasmid DNA (Promega) and 2.5 ng of 
pRL-TK plasmid DNA, using GeneJuice. After 18 hours 
of transfection, the cells were cultured in the presence 
or absence of CsA or FK506 for 24 hours. Cell lysates 
were then assayed for luciferase activity determined using 
a Dual-Luciferase Reporter Assay kit (Promega) and 
luminometer.
RT and real-time PCR
Total RNA (0.5 μg) isolated from cultured cells 
using TRIzol (Invitrogen) was reverse transcribed using 
1 μM oligo (dT) primers and 4 units of Omniscript 
reverse transcriptase (Qiagen) in a total volume of 
20 μL. Real-time PCR was then performed, using SYBR 
GreenER qPCR superMix for iCycler (Invitrogen), 
as described previously [32]. The following primer 
pairs were used for RT-PCR: NFATc1 (forward, 
5′-GTCCCACCACCGAGCCCACTACG-3′; reverse, 
5′-GACCATCTTCTTCCCGCCCACGAC-3′), MMP-2 
(forward, 5′-TACAGGATCATTGGCTACACACC-3′; 
reverse, 5′-GGTCACATCGCTCCAGACT-3′), MMP-9  
(forward, 5′-TGTACCGCTATGGTTACACTCG-3′; 
reverse, 5′-GGCAGGGACAGTTGCTTCT-3′), COX-2 
(forward, 5′-CTGGCGCTCAGCCATACAG -3′; reverse, 
5′-CGCACTTATACTGGTCAAATCCC-3′), and c-myc 
(forward, 5′-ACCAGATCCCGGAGTTGGAA-3′; 
reverse, 5′-CGTCGTTTCCGCAACAAGTC-3′). GAPDH 
(forward, 5′-CTCCTCCACCTTTGACGCTG-3′; reverse, 
5′-CATACCAGGAAATGAGCTTGACAA-3′) was used 
as an internal control.
Western blotting
Protein extraction and western blotting were 
performed, as described previously [28, 34, 35] 
with minor modifications. We also used a nuclear 
and cytoplasmic extraction reagent kit (NE-PER, 
ThermoScientific) for obtaining separate nuclear 
and cytoplasmic fractions. Equal amounts of protein 
(30–50 μg) obtained from cell extracts were separated in 
10% sodium dodecyl sulfate (SDS)-polyacrylamide gel 
Oncotarget1591www.impactjournals.com/oncotarget
electrophoresis (PAGE) and transferred to polyvinylidene 
difluoride membrane (Immun-Blot PVDF Membrane, 
Bio-Rad) by electroblotting. Specific antibody binding 
was detected, using an anti-NFATc1 antibody (clone 7A6; 
dilution 1:500; Abcam), an anti-COX-2 (dilution 1:2000; 
Cayman Chemical), or an anti-GAPDH antibody (clone 
6C5; dilution 1:5000; Santa Cruz Biotechnology), and a 
secondary antibody (mouse IRDye 680LT or rabbit IRDye 
800CW, LI-COR), followed by scanning with an infrared 
imaging system (Odyssey, LI-COR).
Colony formation
Cells (1 x 103) seeded in 6-well plates and cultured 
in the presence or absence of CsA or FK506 were allowed 
to grow until colonies in the control well were easily 
distinguishable. The cells were then fixed with methanol 
and stained with 0.1% crystal violet in phosphate-
buffered saline (PBS). The number of colonies and their 
areas were quantitated using ImageJ software (National 
Institute of Health).
Cell migration
In order to evaluate the ability of cell migration, 
a scratch wound healing assay was performed. Cells at 
a density of 90–100% confluence in 6-well plates were 
scratched manually with a sterile 200 μl plastic pipette 
tip, cultured in the presence or absence of CsA or FK506 
for 24 hours, fixed with methanol, and stained with 0.1% 
crystal violet in PBS. The width of the wound area was 
quantitated, using ImageJ.
Cell invasion
Cell invasiveness was determined, using a Matrigel 
(60 μg; BD Biosciences)-coated transwell chamber 
(8.0 μm pore size polycarbonate filter with 6.5 mm 
diameter; Corning), as described previously [34]. Briefly, 
cells (5 x 104) in 100 μL of serum-free medium were 
added to the upper chamber of the transwell, whereas 600 
μL of medium containing 5% FBS was added to the lower 
chamber. The media in both chambers contained ethanol, 
CsA, or FK506. After incubation for 24 hours at 37°C in 
a CO
2
 incubator, invaded cells were fixed, stained with 
0.1% crystal violet, and counted under a light microscope.
Gelatin zymography
The gelatinolytic activity of MMPs was determined 
by SDS-PAGE gelatin zymography. Cells at a density of 
60–70% confluence in 10-cm dish were cultured in serum-
free medium containing ethanol, CsA, or FK506 for 24 hours 
at 37°C in a CO
2
 incubator. The conditioned medium was 
concentrated using Amicon Ultra-4 centrifugal filter units 
(30 kDa, Millipore) according to the manufacturer’s 
instructions. An equal volume of the zymogram sample 
buffer (Bio-Rad) was added to the concentrated medium 
followed by 10% SDS-PAGE in a gel containing 0.1% 
gelatin (Sigma). After electrophoresis, the gel was rinsed 
with a renaturing buffer (Bio-Rad) for 60 minutes to remove 
SDS, incubated overnight in a developing buffer (Bio-Rad) 
at 37°C with shaking, and stained with 0.25% Coomassie 
Brilliant Blue R-250 (Bio-Rad). MMP activities were 
detected as non-staining regions in the gel, using ChemiDoc 
XRS+ System (Bio-Rad).
Immunofluorescent staining
Cells plated onto 8-well chamber slides (NuncLab-
Tek, Thermo Scientific) were cultured in DMEM with 5% 
CS-FBS containing ethanol, CsA, or FK506 for 24 hours. At 
the end of the drug treatment, the adherent cells were rinse 
twice with PBS and then fixed by 4% paraformaldehyde. 
The cells were blocked with 1% bovine serum albumin 
for 1 hour at 37°C, and a primary antibody (NFATc1; 
clone 7A6; dilution 1:50; Santa Cruz Biotechnology) was 
added and incubated overnight at 4°C. 4’,6’-diamidino-
2-phenylindole (DAPI) was used to visualize nuclei. 
Fluorescence images were acquired with a fluorescence 
microscopy (EVOS FL Auto, Life Technologies).
Apoptosis and cell cycle analysis
The TUNEL assay was performed on cell-burdening 
coverslips, using the DeadEnd Fluorometric TUNEL 
system (Promega), followed by counterstaining for 
DNA with DAPI. Apoptotic index was determined in the 
cells visualized by the fluorescence microscopy (EVOS 
FL Auto). For cell cycle analysis, flow cytometry was 
performed. Cells (1 x 106/10-cm dish) were cultured in 
medium supplemented with CS-FBS containing ethanol, 
CsA, or FK506 for 24 hours, harvested with trypsin, fixed 
in 70% ethanol, and stained with propidium iodide (PI) 
buffer (50 μg/mL) for 60 minutes. Cellular PI content 
was measured on a Guava PCA-96 Base SystemTM flow 
cytometer (EMD Millipore) equipped with a green laser at 
532 nm wavelength. Data were analyzed, using the Guava 
Cell Cycle software (EMD Millipore).
Mouse xenograft model
Animal protocols in accordance with the National 
Institute of Health Guidelines for the Care and Use of 
Experimental Animals were approved at our institution. 
UMUC3 (1 x 106 cells/100 μL/site) resuspended in 
Matrigel (BD Biosciences) were subcutaneously injected 
into the flank of 6-week-old male immunocompromised 
NOD-SCID mice (Johns Hopkins Animal Resources). 
Treatment was initiated when the tumor volume reached 
100 mm3. Mice intraperitoneally received 30 mg/kg/day 
CsA, 3 mg/kg/day FK506, or vehicle control (corn oil) 
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once-daily. Serial caliper measurements of perpendicular 
diameters were used to calculate tumor volume by the 
following formula: (short diameter)2 x (longest diameter) 
x 0.5.
Bladder TMA and immunohistochemistry
We retrieved bladder tissue specimens obtained 
by transurethral resection or cystectomy performed at 
the Johns Hopkins Hospital and University of Rochester 
Medical Center. Appropriate approval from the 
institutional review board at each institution was obtained 
before construction and use of the TMA. Bladder TMAs, 
consisting of 65 cases of muscle-invasive high-grade 
urothelial carcinoma, were constructed from formalin fixed 
paraffin embedded specimens, as described previously 
[36]. All these patients, including 51 men and 14 women 
with a mean/median age of 64.5/66 years (range: 40–89 
years) and a mean/median follow-up of 35.4/16 months 
(range: 2–268 months), ultimately underwent cystectomy. 
None of the patients had received therapy with radiation 
or anti-cancer drugs prior to the collection of the tissues 
included in the TMAs.
Immunohistochemical staining was performed 
on the sections (5 μm thick) from the bladder TMAs or 
mouse xenograft tumors, as described previously [34–36]. 
Briefly, after deparaffinization, hydration, and antigen 
retrieval, samples were incubated overnight at 4°C with 
a primary antibody to NFATc1 (clone 7A6; dilution 
1:50; Santa Cruz Biotechnology) or Ki-67 (clone 30-
9; prediluted; Ventana) and then with a broad spectrum 
secondary antibody (Invitrogen). All stains were manually 
quantified by a single pathologist (H.M.) blinded to sample 
identify. For NFATc1 staining in the bladder TMAs, the 
German immunoreactive scores calculated by multiplying 
the percentage of immunoreactive cells (0% = 0; 1–10% 
= 1; 11–50% = 2; 51–80% = 3; 81–100% = 4) by staining 
intensity (negative = 0; weak = 1; moderate = 2; strong = 3) 
were considered negative (0; 0–1), weakly positive (1+; 
2–4), moderately positive (2+; 6–8), and strongly positive 
(3+; 9–12).
Statistical analysis
The Fisher exact test and the χ2 test were used to 
evaluate the associations between categorized variables. 
The numerical data were compared by Student’s 
t-test. Correlations between variables were determined 
by Spearman’s correlation analysis. Survival rates in 
patients were calculated by the Kaplan-Meier method and 
comparison was made by log-rank test. P values less than 
0.05 were considered to be statistically significant.
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